Karyopharm Therapeutics Inc. (NASDAQ:KPTI) will release its earnings data before the market opens on Tuesday, August 8th. Analysts expect Karyopharm Therapeutics to post earnings of ($0.64) per share for the quarter.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, May 4th. The company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.04. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.02 million. Karyopharm Therapeutics had a negative return on equity of 72.41% and a negative net margin of 50,646.40%. During the same quarter in the previous year, the company posted ($0.75) EPS. On average, analysts expect Karyopharm Therapeutics to post $-2.63 EPS for the current fiscal year and $-2.61 EPS for the next fiscal year.

Karyopharm Therapeutics Inc. (KPTI) opened at 8.31 on Monday. Karyopharm Therapeutics Inc. has a 12 month low of $6.27 and a 12 month high of $14.63. The firm’s 50-day moving average is $9.31 and its 200-day moving average is $10.11. The stock’s market cap is $391.55 million.

KPTI has been the subject of several analyst reports. Robert W. Baird reissued an “outperform” rating and set a $15.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, July 4th. ValuEngine downgraded shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 25th. Jefferies Group LLC reissued a “buy” rating and set a $16.00 price target on shares of Karyopharm Therapeutics in a report on Friday, July 14th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Thursday, July 6th. Finally, BidaskClub downgraded shares of Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Karyopharm Therapeutics presently has a consensus rating of “Buy” and an average target price of $14.46.

COPYRIGHT VIOLATION NOTICE: “Karyopharm Therapeutics Inc. (KPTI) Scheduled to Post Earnings on Tuesday” was first published by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/07/karyopharm-therapeutics-inc-kpti-scheduled-to-post-earnings-on-tuesday.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.